Evolva Holding SA

Equities

EVE

CH1262055788

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 11:30:02 2024-05-17 am EDT			5-day change	1st Jan Change
0.95 ^CHF	+5.56%		-3.85%	+31.94%

Apr. 15	Evolva Shareholders Pass Resolutions to Revoke Liquidation, Delisting	MT
Mar. 26	Evolva Secures Temporary Exemption from Listing Rules Amid Liquidation	MT

Evolva Holding SA Provides Earnings Guidance for the Year 2019

February 28, 2019 at 01:41 am EST

Evolva Holding SA provided earnings guidance for the year 2019. The company expects the trend in product sales growth to continue in 2019. This will be supported by further growing the sales pipeline, increasing geographical marketing reach and launching new product variants. R&D revenues, mainly related to the BARDA project, are expected to remain around the 2018-level. The revenue contribution from royalty payments related to EverSweetTM sweetener sales should start to increase in the course of 2019.

Latest news about Evolva Holding SA

Evolva Shareholders Pass Resolutions to Revoke Liquidation, Delisting	Apr. 15	MT
Evolva Secures Temporary Exemption from Listing Rules Amid Liquidation	Mar. 26	MT
Evolva Closes CHF20 Million Unit Sale to Lallemand's Danstar Ferment	Dec. 28	MT
Danstar Ferment AG completed the acquisition of Evolva AG form Evolva Holding SA.	Dec. 27	CI
Evolva Shareholders OK Unit Sale, Proposed Liquidation	Dec. 22	MT
Evolva to Seek Shareholder Nod for Unit Sale, Proposed Liquidation	Nov. 30	MT
Evolva Strikes CHF20 Million Deal to Sell Business to Lallemand's Danstar Ferment	Nov. 21	MT
Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA for CHF 30 million.	Nov. 20	CI
Evolva, Breko Sign Distribution Deal for Dietary Supplement Ingredient	Nov. 14	MT
Evolva and Breko GmbH Broaden Partnership by Signing Agreement for the Exclusive Distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam	Nov. 14	CI
Evolva Signs Distribution Deal with Chemical Group Lehvoss	23-09-28	MT
Evolva and LEHVOSS Sign Agreement for Distribution of Veri-teTM Resveratrol in over A Dozen European Countries	23-09-28	CI
Evolva, Nice & Green Agree to Term Amendments for CHF5 Million Facility	23-09-13	MT
Evolva Wins Thai Regulatory Nod for Nature-based Ingredient Veri-teTM Resveratrol	23-09-06	MT
Evolva Receives Approval for Veri-Te Resveratrol in Thailand	23-09-06	CI
Evolva Shareholders Greenlight Proposed Conditional Capital Increase Under New Financing Deal	23-08-24	MT
Transcript : Evolva Holding SA, H1 2023 Earnings Call, Aug 24, 2023	23-08-24
Evolva Posts Larger H1 Loss; Revenue Slides Down	23-08-24	MT
Evolva Holding SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22	CI
Evolva Gets Approval for Veri-te Resveratrol Use in Taiwan	23-07-25	MT
Evolva Receives FDA Approval for Veri-teTM Resveratrol in Taiwan	23-07-25	CI
SIX Group Makes Index Adjustments Following Review	23-07-11	MT
Global markets live: Nvidia, IBM, Ford, Pfizer, Lucid Group...	23-06-26
Evolva Secures New Financing Until 2023-end	23-06-26	MT
Evolva Withdraws FY23 Guidance Amid Strategic Financing Review	23-06-14	MT

Chart Evolva Holding SA

Duration

Period

More charts

Company Profile

Evolva Holding Ltd is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVOLVA HOLDING SA	+31.94%	7.55M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research